Table IV. Clinical and laboratory characteristics of patients receiving anagrelide or hydroxyurea as a cytoreductive monotherapy.

¹Values denote median and interquartile range, in anagrelide arm: n=73 and in hydroxyurea arm: n=37. IQR: Interquartile range; MPN: myeloproliferative neoplasms; PV: polycythemia vera; ET: essential thrombocythemia; PMF: primary myelofibrosis; IPSET-thrombosis: International Prognostic Score for thrombosis for ET; MPs: microparticles; PMPs: platelet microparticles; RMPs: erythrocyte microparticles; MPactivity: procoagulant activity of microparticles. Significant p-Values are shown in bold.